MTOR and lymphangioleiomyomatosis: Further, the combination of bevacizumab and temsirolimus has shown preliminary evidence of activity in other tumors in which activation of the PI3 kinase/AKT/mTOR axis has been implicated, including salivary duct tumors [50] and lymphangioleiomyomatosis [51].